Ottawa, Ontario — Friday May 10, 2024
Until now, no patient registries have existed in Canada for mucopolysaccharide (MPS) and phenylketonuria (PKU) – both rare, inherited metabolic diseases which result in developmental disabilities and other neurological problems.
Thanks to federal funding through the Canadian Institute of Health Research (CIHR), The Canadian MPS Registryand The Canadian PKU Registry were launched on May 2, 2024, at the Garrod Symposium in Ottawa. These registries are the first implementation of a National Organization for Rare Disorders (NORD) registry outside of the United States, built in close partnership with patients, clinicians, and researchers.
“To have rare disease drugs approved in Canada, we need to have Canadian clinical trials – these types of registries are critical to that process,” said Dr. Pranesh Chakraborty, Investigator at the CHEO Research Institute (CHEO RI) and Principal Investigator for the patient registries portion of the broader INFORM RARE project. “If companies can see how many people in Canada are impacted by a rare disease, it strengthens the case to bring important clinical trials to Canada.”
These registries will help document the natural history of MPS an PKU in Canada – allowing clinicians to further understand the experiences and priorities of Canadian patients/caregivers as they change over time. Patients/caregivers will also have access to their own data and group-level information about all participants, empowering families with what to expect with the rare disease and providing a shared experience to know they are not alone.
“This registry represents a crucial advancement in our efforts to understand and support individuals with MPS disorders. By consolidating data from across Canada, the registry will provide invaluable insights into the prevalence, progression, and management of MPS in pediatric patients. This initiative underscores our commitment to improving the lives of those affected by MPS and will serve as a cornerstone for future research and therapeutic developments. We are grateful for the collaboration with INFORM RARE and look forward to the positive impact this registry will have on our community,” said Kim Angel, Executive Director, Canadian MPS Society.
“We are thrilled by the launch of these registries which will move us forward in our mission to support families and professionals dealing with PKU and similar, rare, inherited metabolic disorders. This incredible advancement in data collection capabilities, functioning in both official languages and hosted on Canadian servers, is a significant step towards better understanding rare diseases and how they change over time for different patients. We are immensely grateful for our partnership with INFORM RARE and the opportunities it presents for changing the lives of those in our community affected by PKU,” said John Adams, CEO & Co-Founder, Canadian PKU and Allied Disorders
“Rare disease research succeeds when as many patients as possible can participate, and we know that one-size patient registries do not fit all,” said NORD CEO, Pamela K. Gavin. “Patient registries need to account for the diversity of patient backgrounds and experiences as well as the diversity of regulations and requirements that must be met to ensure participation of both patients and researchers.”
These registries will also provide researchers a platform to invite patients and their caregivers to participate in research and will help to inform the development of future clinical trials in Canada – allowing Canadian researchers to lead the way in gathering real-world evidence through these registries, so we can invest funding in the right places and build capacity for future Canadian clinical trials.
The CHEO RI is the academic institution responsible for the research oversight of the PKU and MPS patient registries. Decision-making regarding these registries will be led by the PKU and MPS Patient Registries Steering Committees.
These registries have been developed in partnership with The Canadian MPS Society, Canadian PKU and Allied Disorders Inc. (CanPKU+), INFORM RARE research network, the CHEO RI, and NORD.
The Canadian Organization for Rare Disorders Hereby Gives Notice of its Annual General Meeting: August 26, 2024 at 2:00 PM (EDT) via videoconference
CORD Annual General MeetingAugust 26, 2024 at 2:00 PM (EDT) via videoconference Dear CORD Members: The Canadian Organization for Rare Disorders gives notice of it's Annual General Meeting on August 26, 2024 at 2pm - 3pm (Eastern Time). All individual, affiliate and corporate members in good standing are invited participate. An eligible voter must be a representative of a voting member of CORD. Eligible voters may either vote at the upcoming Annual General Meeting videoconference or by proxy. Votes by proxy must be in must be returned to us by August 25, 2024. Ballots received after this date and time, duplicate votes and spoiled ballots will not be counted. To participate in the AGM teleconference, please register by August 25, 2024 Registration: https://bit.ly/4aM8IJL Once we have received your response, we will email you the teleconference details and any other necessary documents that will be required for the meeting. Thank you for your participation and if you have any questions, please let me know. Sincerely, Christine White CORD Secretary PROXY-2024Download
The Canadian Organization for Rare Disorders Hereby Gives Notice of its Annual General Meeting: August 26, 2024 at 2:00 PM (EDT) via videoconference
CORD Annual General MeetingAugust 26, 2024 at 2:00 PM (EDT) via videoconference Dear CORD Members: The Canadian Organization for Rare Disorders gives notice of it's Annual General Meeting on August 26, 2024 at 2pm - 3pm (Eastern Time). All individual, affiliate and corporate members in good standing are invited participate. An eligible voter must be a representative of a voting member of CORD. Eligible voters may either vote at the upcoming Annual General Meeting videoconference or by proxy. Votes by proxy must be in must be returned to us by August 25, 2024. Ballots received after this date and time, duplicate votes and spoiled ballots will not be counted. To participate in the AGM teleconference, please register by August 25, 2024 Registration: https://bit.ly/4aM8IJL Once we have received your response, we will email you the teleconference details and any other necessary documents that will be required for the meeting. Thank you for your participation and if you have any questions, please let me know. Sincerely, Christine White CORD Secretary PROXY-2024Download
Join us and become part of an active Canadian rare disorder community. The only national organization representing all rare disorder patient groups in Canada.
LEARN MORE